CheckCap (CHEK)
(Delayed Data from NSDQ)
$2.29 USD
+0.02 (0.66%)
Updated Apr 26, 2024 03:57 PM ET
After-Market: $2.30 +0.02 (0.66%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CHEK 2.29 +0.02(0.66%)
Will CHEK be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CHEK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CHEK
Here's Why You Should Retain Cardinal Health (CAH) Stock Now
3 Reasons to Retain Baxter (BAX) Stock in Your Portfolio
CHEK: What are Zacks experts saying now?
Zacks Private Portfolio Services
CheckCap Ltd. (CHEK) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
The Zacks Analyst Blog Highlights ShockWave Medical, CheckCap and Biosig Technologies
3 Medical Instruments Stocks With Potential to Outperform
Other News for CHEK
Check-Cap Ltd. Calls for Shareholder Vote
Check-Cap Ltd. Approaches Key Merger Vote
Check-Cap, Outset Medical, Vincerx Pharma among healthcare movers
Check-Cap Ltd. Calls Shareholders to Vote on Key Proposals
CHEK, HKIT and GCTS among pre-market losers